Table 3 The distribution of gender per indication, comorbidities, previous episodes of the indication and the number of follow-ups]
From: Examining GP online consultation in a primary care setting in east midlands, UK
|  | Total | Men | Women | 0 co-morbidities | 1 co-morbidity | 2 co-morbidities | 3 ≥ co-morbidities | 0 previous episodes | 1 previous episode | 2 previous episodes | 3 previous episodes | 4 previous episodes | 5 previous episodes | 5 ≥ previous episodes | 0 follow ups | 1 follow up | 2 follow ups | 3 follow ups | 4 follow ups | 5 follow ups | 5 ≥ follow ups |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tonsillitis | 51 (27.9%) | 17 (33.3%) | 34 (66.7%) | 16 (31.4%) | 16 (31.4%) | 7 (13.7%) | 12 (23.5%) | 31 (60.8%) | 15 (29.4%) | 3 (5.9%) | 1 (2.0%) | 1 (2.0%) | – | – | 6 (11.8%) | 10 (19.6%) | 7 (13.7%) | 5 (9.8%) | 8 (15,7%) | 3 (5.9%) | 12 (23.5%) |
Cough | 43 (22.4%) | 16 (37.2%) | 27 (62.8%) | 10 (23.3%) | 9 (20.9%) | 9 (20.9%) | 15 (34.9%) | 17 (39.5%) | 9 (20.9%) | 8 (18.6%) | 5 (11.6%) | 1 (2.3%) | 1 (2.3%) | 2 (4.7%) | 2 (4,7%) | 11 (25,6%) | 8 (18,6%) | 6 (14.0%) | 4 (9.3%) | 2 (4.7%) | 10 (23.3%) |
UTI | 33 (17.4%) | – | 33 (100.0%) | 11 (33.3%) | 13 (39,4%) | 1 (3.0%) | 8 (24.2%) | 16 (48.5%) | 7 (21.2%) | 4 (12.1%) | 2 (6.1%) | 2 (6.1%) | 1 (3.0%) | 1 (3.0%) | 3 (9.1%) | 8 (24,2%) | 6 (18,2%) | 5 (15,2%) | 3 (9,1%) | 2 (6,1%) | 6 (18,3%) |
Acne | 20 (10.5%) | 2 (10.0%) | 18 (90.0%) | 9 (45.0%) | 3 (15.0%) | 2 (10.0%) | 6 (30.0%) | 11 (55.0%) | 5 (25.0%) | 4 (20%) | – | – | – | – | 4 (20.0%) | 5 (25.0%) | 6 (30.0%) | 2 (10.0%) | – | 2 (10.0%) | 1 (5.0%) |
Vaginosis | 18 (9.6%) | – | 18 (100.0%) | 5 (27.8%) | 4 (22.2%) | 5 (27.8%) | 4 (22.2%) | 14 (77.8%) | 4 (22.2%) | – | – | – | – | – | 2 (11,1%) | 3 (16,7%) | 3 (16,7%) | 2 (11,1%) | 2 (11,1%) | 1 (5,6%) | 5 (27,8%) |
Sinusitis | 14 (6.9%) | 3 (21.4%) | 11 (78.6%) | 1 (7.1%) | 3 (21.4%) | 3 (21.4%) | 7 (50.0%) | 7 (50.0%) | 5 (35.7%) | 1 (7.1%) | – | – | – | 1 (7.1%) | 4 (28,6%) | 2 (14,3%) | 1 (7,1%) | 1 (7,1%) | 3 (21,4%) | – | 3 (21,4%) |
Eczema | 10 (5.4%) | 3 (30.0%) | 7 (70.0%) | 1 (10.0%) | 2 (20.0%) | 2 (20.0%) | 5 (50.0%) | 3 (30.0%) | 3 (30.0%) | 2 (20.0%) | 2 (20.0%) | – | – | – | 3 (30%) | 1 (10.0%) | 2 (20.0%) | 1 (10.0%) | 2 (20.0%) | – | 1 (10.0%) |